M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Liver Cancer Prevention Randomized Control Trial

Not Applicable

Recruiting

Conditions: Liver Diseases
Cirrhosis, Liver
Fibrosis, Liver

Interventions: Behavioral: Intervention Group
Behavioral: Control Group

First Posted Date: 2022-01-19

Last Posted Date: 2024-10-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 266

Registration Number: NCT05196867

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Phase 2

Withdrawn

Conditions: Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Anatomic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Breast Inflammatory Carcinoma
Invasive Breast Carcinoma
Prognostic Stage III Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage IIIB Breast Cancer AJCC v8

Interventions: Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Paclitaxel
Biological: Panitumumab
Biological: Pembrolizumab

First Posted Date: 2022-01-05

Last Posted Date: 2024-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05177796

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Molecular Epidemiology of Biliary Tree Cancers

Recruiting

Conditions: Cholangiocarcinoma
Malignant Digestive System Neoplasm

Interventions: Procedure: Biospecimen Collection
Other: Questionnaire Administration

First Posted Date: 2022-01-05

Last Posted Date: 2024-11-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1500

Registration Number: NCT05179486

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

18F-FDG PET-MRI for Planning and Follow-Up of Patients With Spine Tumors Treated With Spine Stereotactic Radiosurgery

Not Applicable

Completed

Conditions: Metastatic Malignant Neoplasm
Metastatic Malignant Neoplasm in the Bone

Interventions: Other: Fludeoxyglucose F-18
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2021-12-30

Last Posted Date: 2024-06-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT05174026

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA Study

Withdrawn

Conditions: Hodgkin Lymphoma
Malignant Solid Neoplasm
Non-Hodgkin Lymphoma
Sarcoma
Central Nervous System Neoplasm

Interventions: Other: Smartphone Application

First Posted Date: 2021-12-23

Last Posted Date: 2023-04-24

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05169151

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Prospective Study of Performing MRI Simulation in Treatment Position in Spinal Stereotactic Body Radiation Therapy

Active, not recruiting

Conditions: Spinal Metastases

Interventions: Other: mask for immobilization
Other: Elekta BodyFix

First Posted Date: 2021-12-13

Last Posted Date: 2024-12-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT05155423

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Risk and Benefits of Electronic Cigarettes to Older Smokers At High Risk for Lung Cancer

Not Applicable

Recruiting

Conditions: Lung Carcinoma

Interventions: Procedure: Participants smoke their usual brand of cigarettes for 26 weeks.
Procedure: Participants will vape electronic cigarettes for 26 weeks.
Drug: Nicotine Replacement
Other: Questionnaire Administration

First Posted Date: 2021-12-03

Last Posted Date: 2024-11-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 140

Registration Number: NCT05144542

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Other: Survey Administration

First Posted Date: 2021-12-03

Last Posted Date: 2024-10-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT05143619

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

Phase 2

Recruiting

Conditions: Urothelial Carcinoma
Bladder Cancer

Interventions: Other: Abiraterone acetate
Drug: Durvalumab
Drug: Methotrexate
Drug: Vinblastine
Drug: Doxorubicin Hydrochloride
Drug: Cisplatin

First Posted Date: 2021-11-30

Last Posted Date: 2024-11-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT05137262

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

Recruiting

Conditions: Monoclonal Gammopathy of Undetermined Significance
Smoldering Plasma Cell Myeloma

Interventions: Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2021-11-29

Last Posted Date: 2024-11-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 400

Registration Number: NCT05136807

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy